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Abstract
Systemic lupus erythematosus (SLE) is a multi-system inflammatory disorder characterized by the presence of
several autoantibodies, including anti-double-stranded DNA. Neuropsychiatric (NP)LE contributes to the prognosis
of SLE, and is divided into 19 NPLE syndromes. Its mechanisms are mediated through autoantibodies, complement
components, and cytokines. The pathophysiology and diagnosis of NPLE are diverse and complicated. Recent
studies have shown that several autoantibodies cross-react with human brain tissue and cause NPLE symptoms in
SLE. It is known that in mice, depression and hippocampus-related memory impairment are induced by anti-
ribosomal P antibody and anti-NR2 antibody, respectively. In a BMC Medicine research article, Kivity et al.
demonstrated novel work showed that the 16/6 Id antibody impaired visual memory and spatial memory by
causing hippocampal injury in mice. Given differences in the cross-reactivity of each autoantibody with the nervous
system, the clinical features might be different and diverse in NPLE. Identification of autoantibody targets could
lead to the development of novel therapies. Investigators and clinicians should consider not only the inhibition of
autoantibody synthesis but also the protection of neuronal cells in the treatment strategy for NPLE.
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Introduction
Systemic lupus erythematosus (SLE) is a multi-system
inflammatory disorder characterized by the presence of
autoantibodies directed against double-stranded (ds)
DNA. The prevalence ranges from 20 to 150 cases per
100,000 population, and it seems to be increasing, partly
because the disease is recognized more readily and partly
because of longer survival [1]. Specifically, lupus nephritis,
which is a kidney disorder that is a complication of SLE,
and neuropsychiatric (NP)LE contribute to the prognosis
of SLE.
NPLE is classified by the American College of Rheumatol-
ogy (ACR) into 19 neuropsychiatric syndromes [2]. The dif-
fuse central nervous system (CNS) form, focal CNS form,
and peripheral nervous system (PNS) form were defined as
diffuse psychiatric/neuropsychological syndromes, neurologic
syndromes, and PNS syndromes, respectively, by the ACR.
The pathophysiology of NPLE is mediated by several factors,
including vasculitis, thromboembolism, and inflammation
and apoptosis of neuronal and glial cells. Its mechanisms are
mediated through autoantibodies, complement components,
cytokines, chemical mediators, and inflammatory cells, in-
cluding neutrophils, lymphocytes, and plasma cells. Thus,
the pathophysiology and diagnosis of NPLE are diverse and
complicated, which makes therapy difficult. The diagnosis of
NPLE is based on the results of several investigations, includ-
ing neurological examination, brain/spinal cord magnetic
resonance imaging, electroencephalography, cerebrospinal
fluid analysis, nerve-conduction studies, psychiatric inter-
view, and a short battery of neuropsychological tests reco-
mmended by the ACR committee [2].
Recent novel studies have identified some aspects of the
pathophysiology of NPLE. Some anti-dsDNA antibodies
cross-react with the N-methyl-D-aspartate (NMDA)
receptor subunit 2 (NR2) in SLE [3]. NMDA receptors are
ligand-gated ion channels that play crucial roles in synap-
tic transmission and CNS plasticity. NMDA receptor
dysfunction has been implicated in multiple brain disor-
ders, including stroke, chronic neurodegeneration, epilepsy,
* Correspondence: tgono@ior.twmu.ac.jp
Institute of Rheumatology, Tokyo Women’s Medical University, 10-22
Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
© 2013 Gono et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gono et al. BMC Medicine 2013, 11:91
http://www.biomedcentral.com/1741-7015/11/91
and schizophrenia. Anti-NR2 antibodies breaching the
blood–brain barrier (BBB) can cause neuronal damage via
an apoptotic pathway [4,5].
The 16/6 idiotype (Id) antibody, which was the focus of a
recent study by Kivity et al. [6], is considered to be an anti-
dsDNA Id antibody in SLE. Immunization of naive mice
with the human 16/6 Id monoclonal antibody induced an
SLE-like disease characterized by serological, clinical, and
pathological features. This antibody cross-reacts with cyto-
skeletal proteins, glycoproteins, and brain glycolipids, as
well as with pathogens such as Mycobacterium tuberculosis
[7]. Deposition of 16/6 Id antibodies has been found in
human tissues, such as the skin, kidney, and brain [8], and
levels are high in patients with active SLE or NPLE [9].
These findings indicate that the 16/6 Id antibody is poten-
tially one of the factors that cause NPLE. However, the way
in which these neuropsychiatric symptoms are induced
by the 16/6 Id antibody reaching the CNS and the under-
lying mechanisms of this induction are unknown. In their
study, Kivity et al. showed for the first time the effect of
the 16/6 Id antibody on the CNS by injecting naive mice
intracerebroventricularly with the 16/6 Id antibody [6]. In
this commentary, we discuss their results and the patho-
physiology and treatment strategy for NPLE.
Neurological effects of the 16/6 Id antibody
To understand if the 16/6 Id IgG antibody is able to induce
neurological effects, Kivity et al. compared the cognitive
and behavioral performance of C3H female mice that had
been injected with the human 16/6 Id IgG antibody (16/6
Id mice subset) and those injected with a commercial hu-
man IgG (control mice subset) [6]. Visual-recognition
memory was assessed by using the novel-object recogni-
tion test. The authors found that there was a significant
preference for attention to the new object compared with
the old object by the control mice, but no difference in
preference was found between the new and the old objects
by the 16/6 Id mice. This result indicates impairment of
visual-recognition memory in the 16/6 Id mice. In the Y-
maze test, which assesses spatial memory, the 16/6 Id mice
were also found to have impairment of spatial memory.
In addition, the brain pathology of these mice was ex-
amined to establish the potential mechanism by which
the 16/6 Id IgG antibody is able to exert its neurological
effects. In the brain tissue, increased microglial activa-
tion was seen in the hippocampus and amygdala, but
not in the neurocortex or piriform cortex. In addition,
the number of astrocytes in the hippocampus was found
to be increased. Taken together, these results show that
in mice, the 16/6 Id antibody causes impairment of both
visual and spatial memory through hippocampal injury,
and might selectively cross-react with some antigens in
the hippocampus.
The 16/6 Id antibody is a novel antibody contributing to
the pathophysiology of NPLE
Kivity et al. also showed that, in addition to the anti-
ribosomal P and anti-NR2 antibodies, another autoanti-
body, anti-16/6 Id antibody, can cross-react with human
brain tissue and cause NPLE symptoms in SLE [6]. Brain
tissue-reactive antibodies in NPLE are thought to be syn-
thesized in the CNS or peripheral organs, such as the
lymph nodes and bone marrow [10]. Therefore, if NPLE is
associated with antibodies reaching the CNS through the
BBB, treatments that not only eliminate brain-tissue-react-
ive antibodies but also protect the integrity of the BBB
should be considered.
Therapy of NPLE is currently difficult. Although corti-
costeroids and immunosuppressive agents, such as
cyclophosphamide, are broadly effective for NPLE, the
condition is occasionally refractory to these treatments.
Moreover, brain-tissue-reactive autoantibodies might
cause irreversible neuronal degeneration via apoptosis.
For instance, anti-ribosomal P antibody targets a neur-
onal surface protein, causing calcium influx and apop-
tosis [11]. These antibodies specifically bind to neurons
in the hippocampus, cingulate cortex, and the primary
olfactory piriform cortex, and, in mice, resulted in the
induction of depression. These results implicate the
olfactory and limbic areas in the pathogenesis of depre-
ssion in SLE [12]. The anti-NR2 antibody also causes
neuronal cell apoptosis, impairs the hippocampus-
dependent memory function in mice, stimulates NMDA
receptor-mediated synaptic responses and excitotoxicity
through enhanced mitochondrial permeability [13]. and
decreases cell viability through increased Ca2+ influx [5].
Kivity et al. showed that the anti-16/6 Id antibody
hampers visual-recognition and spatial memory. Their
hypothesis about the pathophysiology of anti-16/6 Id
antibody-induced brain involvement was that brain in-
flammation induces modification of neuronal function
and neuronal degeneration [6]. The authors also found in-
creases in astrocyte number and microglial activation in
the hippocampus of anti-16/6 Id antibody-injected mice.
They suggested that increased astrocytes and activated
microglial cells were involved in brain inflammation and
therefore, an inflammatory process may affect cognitive
impairment in mice injected with anti-16/6 Id antibody.
By contrast, there was minimal local activation of astro-
cytes and microglial cells, and no lymphocytic inflamma-
tion in the brains of anti-NR2 antibody-injected mice [3].
It is plausible, therefore, that the wide variety of
NPLE syndromes might be caused by differences in
the recognition of brain tissue by lupus autoanti-
bodies, such as anti-ribosomal P, anti-NR2, and anti-
16/6 Id antibodies. Identification and evaluation of
such differences would perhaps be useful in develop-
ing therapies for NPLE.
Gono et al. BMC Medicine 2013, 11:91 Page 2 of 3
http://www.biomedcentral.com/1741-7015/11/91
Future directions and conclusions
In the future, it is hoped that new agents will be developed
to improve the prognosis for NPLE. The efficacy of such
new agents should be determined through their ability to
protect neuronal cells, modulate intracellular Ca2+, or regu-
late the deposition of autoantibodies in NPLE. Memantine
is a drug used to treat Alzheimer’s disease, which modulates
intracellular Ca2+ by blocking NMDA receptors. In addi-
tion, the DWEYS pentapeptide, which the anti-NR2 anti-
body recognizes as an antigen, prevents the anti-NR2
antibody from being deposited in tissues and mediating
neuronal excitotoxicity in mice [14].
As Kivity et al. have shown, several autoantibodies
against brain tissue are involved in NPLE. Given the dif-
ferences in the cross-reactivity of each autoantibody with
the nervous system, this may explain the difference and
diversity of the clinical features in NPLE. Investigators
and clinicians should consider not only inhibition of
autoantibody synthesis but also protection of neuronal
cells when investigating treatment strategies for NPLE.
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